Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Raptor Pharmaceuticals Inc.
ClinicalTrials.gov Identifier:
NCT01000961
First received: October 22, 2009
Last updated: September 17, 2012
Last verified: September 2012

October 22, 2009
September 17, 2012
June 2010
June 2011   (final data collection date for primary outcome measure)
To assess the steady-state white blood cell cystine levels of RP103 compared to Cystagon® [ Time Frame: 4 weeks after the last subject has completed the study ] [ Designated as safety issue: No ]
To assess the steady-state white blood cell cystine levels of RP103 compared to Cystagon® [ Time Frame: Periodically over a 3 day window for each drug ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01000961 on ClinicalTrials.gov Archive Site
  • To assess the safety and tolerability of RP103 compared to Cystagon® [ Time Frame: 4 weeks after the last subject has completed the study ] [ Designated as safety issue: Yes ]
  • To assess the steady state pharmacokinetics and pharmacodynamics of RP103 compared to Cystagon®. [ Time Frame: 4 weeks after the last subject has completed the study ] [ Designated as safety issue: No ]
  • To assess the safety and tolerability of RP103 compared to Cystagon® [ Time Frame: 27-37 days (duration of study) ] [ Designated as safety issue: Yes ]
  • To assess the steady state pharmacokinetics and pharmacodynamics of RP103 compared to Cystagon®. [ Time Frame: Periodically over a 3 day window for each drug ] [ Designated as safety issue: No ]
  • To compare the incidence of concomitant gastric acid reduction therapies [e.g., proton pump inhibitors (PPI)] between Cystagon® and RP103. [ Time Frame: 27-37 days (duration of study) ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis
A Randomized, Crossover Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cystagon® in Patients With Nephropathic Cystinosis

Cystinosis is an inherited disease that if untreated, results in kidney failure as early as the first decade of life. The current marketed therapy is Cystagon® (cysteamine bitartrate) which must be taken every six hours for the rest of the patient's life to prevent complications of cystinosis. RP103 is a formulation of cysteamine bitartrate that is being studied to see if it may be able to be given less frequently, once every 12 hours, and have similar results to four times a day Cystagon®.

This is a multi-center, open-label, randomized, cross-over study to determine whether steady-state, twice a day treatment with Cysteamine Bitartrate Delayed-release Capsules(RP103) results in comparable depletion of white blood cell (WBC) cystine levels compared to the existing four times a day cysteamine treatment. It will involve up to 20 clinic visits plus intermittent home use of the RP103. Most of these clinic visits occur in clusters of 3-4 consecutive days. Eligible patients will be offered enrollment into a long-term follow up study.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Cystinosis
  • Drug: Cystagon® (Cysteamine Bitartrate)

    Run-in Period (Weeks 1, 2, 3) and Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:

    Every 6H, supplied in 150 and 50mg capsules/Duration of Treatment: 3 weeks each period used

  • Drug: Cysteamine Bitartrate Delayed-release Capsules (RP103)

    Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:

    Every 12H, supplied in 75 and 25mg capsules/Duration of Treatment: 3 weeks

  • Experimental: RP103 Q12H
    Intervention: Drug: Cysteamine Bitartrate Delayed-release Capsules (RP103)
  • Active Comparator: Cystagon® Q6H
    Intervention: Drug: Cystagon® (Cysteamine Bitartrate)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
43
August 2011
June 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and female subjects must have nephropathic cystinosis.
  • Subjects must be on a stable dose of Cystagon® sufficient to maintain their white blood cell (WBC) cystine level at ≤ 1.0 nmol/half-cystine/mg protein.
  • Subjects must be able to swallow their typically administered Cystagon® capsule with the capsule intact.
  • Within the last 6 months, no clinically significant change in liver function [i.e., ALT, AST, total bilirubin] and renal function [i.e., estimated GFR] at Screening as determined by the Investigator.
  • Subjects with an estimated GFR (corrected for body surface area) > 30 mL/min/1.73m2.
  • Sexually active female subjects of childbearing potential (i.e., not surgically sterile [tubal ligation, hysterectomy, or bilateral oophorectomy] or at least 2 years naturally postmenopausal) must agree to utilize the same acceptable form of contraception from Screening through completion of the study.
  • Subjects must be willing and able to comply with the study restrictions and requirements.
  • Subjects or their or their parent or guardian must provide written informed consent and assent (where applicable) prior to participation in the study.

Exclusion Criteria:

  • Subject's age < 6 years old or subject's weight < 21 kg.
  • Subjects with a known history, currently of the following conditions or other health issues that make it, in the opinion of the investigator, unsafe for them to participate: inflammatory bowel disease (if currently active) or have had prior resection of small intestine; Heart disease (e.g., myocardial infarction, heart failure, arrhythmias or poorly controlled hypertension) 90 days prior to Screening; Active bleeding disorder 90 days prior to Screening; Malignant disease within the last 2 years.
  • Patients with a hemoglobin level < 10 g/dL at Screening or a level that, in the opinion of the investigator, makes it unsafe for the subject to participate.
  • Subjects receiving any form of cysteamine medication through a gastric tube.
  • Subjects who are receiving maintenance dialysis or who have had a kidney transplant.
  • Subjects who are on an active kidney transplant list or who are planning to receive a kidney transplant within 3 months of Screening.
  • Subjects with known hypersensitivity to cysteamine or penicillamine.
  • Female subjects who are nursing, planning a pregnancy, known or suspected to be pregnant, or have a positive serum pregnancy screen.
  • Subjects who have a made a blood donation within 30 days of Screening.
  • Subjects who, in the opinion of the Investigator, are not able or willing to comply with the protocol.
Both
6 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   France,   Netherlands
 
NCT01000961
RP103-03
No
Raptor Pharmaceuticals Inc.
Raptor Pharmaceuticals Inc.
Not Provided
Principal Investigator: Craig Langman, MD Ann & Robert H. Lurie Children's Hospital of Chicago (formerly Children's Memorial Hospital)
Raptor Pharmaceuticals Inc.
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP